Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Dec 10, 2024
Episode
265
Soundcloud
Share
Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC. The approval was based, in part, on the results of the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Tune in and hear about this important trial from the lead author.
Guest
Suresh Ramalingam
MD, FACP, FASCO
Professor, Department of Hematology and Medical Oncology
Emory University Winship Cancer Institute
